- Home
- BYM vs TIL Comparison
BYM vs TIL Comparison
Compare BYM & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYM
- TIL
- Stock Information
- Founded
- BYM 2002
- TIL 2018
- Country
- BYM United States
- TIL United States
- Employees
- BYM N/A
- TIL N/A
- Industry
- BYM Investment Managers
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- BYM Finance
- TIL Health Care
- Exchange
- BYM Nasdaq
- TIL Nasdaq
- Market Cap
- BYM 271.5M
- TIL 230.1M
- IPO Year
- BYM N/A
- TIL 2021
- Fundamental
- Price
- BYM $10.44
- TIL $24.36
- Analyst Decision
- BYM
- TIL Buy
- Analyst Count
- BYM 0
- TIL 5
- Target Price
- BYM N/A
- TIL $119.00
- AVG Volume (30 Days)
- BYM 60.2K
- TIL 239.2K
- Earning Date
- BYM 01-01-0001
- TIL 08-12-2025
- Dividend Yield
- BYM 4.49%
- TIL N/A
- EPS Growth
- BYM N/A
- TIL N/A
- EPS
- BYM N/A
- TIL N/A
- Revenue
- BYM N/A
- TIL N/A
- Revenue This Year
- BYM N/A
- TIL N/A
- Revenue Next Year
- BYM N/A
- TIL N/A
- P/E Ratio
- BYM N/A
- TIL N/A
- Revenue Growth
- BYM N/A
- TIL N/A
- 52 Week Low
- BYM $9.30
- TIL $9.85
- 52 Week High
- BYM $11.77
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- BYM 52.57
- TIL 51.20
- Support Level
- BYM $10.38
- TIL $25.58
- Resistance Level
- BYM $10.57
- TIL $32.40
- Average True Range (ATR)
- BYM 0.12
- TIL 2.68
- MACD
- BYM 0.01
- TIL 0.07
- Stochastic Oscillator
- BYM 72.34
- TIL 51.03
About BYM Blackrock Municipal Income Quality Trust of Beneficial Interest
Blackrock Municipal Income Quality Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from U.S. federal income taxes, including the alternative minimum tax. The trust invests in various sectors such as transportation, utilities, health, education, corporate, housing, and others.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.